XML 48 R27.htm IDEA: XBRL DOCUMENT
v2.4.1.9

COLLABORATION AND LICENSE AGREEMENT (Details) (USD $) | 0 Months Ended |  |
--- | --- | --- | ---
Dec. 15, 2014 item | Mar. 31, 2015 | Dec. 31, 2014
LICENSE AGREEMENTS |  |  |
Amount expected to be recognized as revenue |  | $ 35,000,000 us-gaap_DeferredRevenueCurrent | $ 35,000,000 us-gaap_DeferredRevenueCurrent
Accrued collaboration charges |  | 626,000 gern_CollaborativeArrangementAccruedCollaborationChargesCurrent |
Expected Revenue |  |  |
LICENSE AGREEMENTS |  |  |
Amount expected to be recognized as revenue |  | 35,000,000 us-gaap_DeferredRevenueCurrent / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementExpectedRevenueMember |
License agreements | Janssen Biotech | Initial Period |  |  |
LICENSE AGREEMENTS |  |  |
Upfront payment received | 35,000,000 gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Number of agreed upon studies | 2 gern_CollaborativeArrangementNumberOfStudies / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Percentage of costs to be paid by Geron | 50.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Percentage of costs to be paid by Janssen | 50.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_InitialPeriodMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Notification period | 24 months |  |
Maximum period Geron is obligated to procure supply for manufacturing imetelstat under collaboration agreement | 9 months |  |
License agreements | Janssen Biotech | U.S. Opt-In Rights exercised |  |  |
LICENSE AGREEMENTS |  |  |
Percentage of costs to be paid by Geron | 20.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Percentage of costs to be paid by Janssen | 80.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Continuation Election milestone payment | 65,000,000 gern_CollaborativeArrangementContinuationElectionMilestonePayment / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement | 470,000,000 gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Aggregate maximum total of payments for sales milestones under collaboration agreement | 350,000,000 gern_CollaborativeArrangementSalesMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Tiered royalties percentage, low end of the range | mid-teens |  |
Tiered royalties percentage, high end of the range | low twenties |  |
U.S. selling effort percentage | 20.00%gern_CollaborativeArrangementSellingEffortPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
License agreements | Janssen Biotech | U.S. Opt-In Rights not exercised |  |  |
LICENSE AGREEMENTS |  |  |
Continuation Election milestone payment | 65,000,000 gern_CollaborativeArrangementContinuationElectionMilestonePayment / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Full U.S. Rights fee | 70,000,000 gern_CollaborativeArrangementFullUSRightsFee / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement | 415,000,000 gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Aggregate maximum total of payments for sales milestones under collaboration agreement | $ 350,000,000 gern_CollaborativeArrangementSalesMilestonesAggregateMaximum / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_RightsNotExercisedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Tiered royalties percentage, low end of the range | double-digit |  |
Tiered royalties percentage, high end of the range | mid-teens |  |
License agreements | Janssen Biotech | Collaborative Arrangement IP Exclusively Licensed |  |  |
LICENSE AGREEMENTS |  |  |
Percentage of costs to be paid by Geron | 50.00%gern_CollaborativeArrangementGeronCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementIPExclusivelyLicensedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |
Percentage of costs to be paid by Janssen | 50.00%gern_CollaborativeArrangementJanssenCostSharingPercentage / us-gaap_CounterpartyNameAxis = us-gaap_CollaborativeArrangementMember / us-gaap_StatementScenarioAxis = gern_CollaborativeArrangementIPExclusivelyLicensedMember / us-gaap_TypeOfArrangementAxis = gern_JanssenBiotechIncMember |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable to collaboration partner for which invoices have not yet been received under the respective collaboration agreement (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | gern_CollaborativeArrangementAccruedCollaborationChargesCurrent
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of consideration that Geron will receive upon Janssen providing a positive Continuation Election notice. + References No definition available. + Details
Name: | gern_CollaborativeArrangementContinuationElectionMilestonePayment
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the aggregate maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the collaboration agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the maximum period that Geron is obligated to Janssen to procure supply for manufacturing imetelstat under the collaboration agreement + References No definition available. + Details
Name: | gern_CollaborativeArrangementDrugSupplyProcurementPeriodMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the consideration that Geron will receive from Janssen upon Geron's decision to opt-out of further development cost sharing after Janssen's positive Continuation Election notice. + References No definition available. + Details
Name: | gern_CollaborativeArrangementFullUSRightsFee
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of costs that Geron must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementGeronCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that Janssen must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementJanssenCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the latest notification period from Janssen to Geron in the event of early termination or suspension of the Initial Phase 2 MF Study. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNotificationPeriod
Namespace Prefix: | gern_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of agreed upon studies. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNumberOfStudies
Namespace Prefix: | gern_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the aggregate maximum consideration that Geron could receive from attaining certain sales milestone events under the collaboration agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementSalesMilestonesAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of sales effort that Geron can provide in lieu of funding the same percentage of promotion costs upon regulatory approval and commercial launch of imetelstat in the U.S. + References No definition available. + Details
Name: | gern_CollaborativeArrangementSellingEffortPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the high end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat. + References No definition available. + Details
Name: | gern_CollaborativeArrangementTieredRoyaltiesPercentageHighEndOfRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the low end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat. + References No definition available. + Details
Name: | gern_CollaborativeArrangementTieredRoyaltiesPercentageLowEndOfRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment received from Janssen upon effectiveness of Collaboration Agreement. + References No definition available. + Details
Name: | gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CounterpartyNameAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=gern_CollaborativeArrangementExpectedRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |